Dr. Reddy's Laboratories Ltd. closed 10.04% short of its 52-week high of 1,420.20 rupees, which the company achieved on August 21st.

Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Dr Reddy's Laboratories share price gained almost 3% in the morning trades on Thursday post Q1 results that were declared ...

RDY reports encouraging first-quarter fiscal 2026 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

Dr. Reddy's Laboratories has kicked off FY26 with double-digit growth. M.V. Ramana, CEO of Branded Markets (India & Emerging ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

On the NSE, 14 out of the 15 sectors ended in the red, with the Nifty Media, Energy, Defence and Oil & Gas declining the most ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

The UK-India Free Trade Agreement is expected to boost trade in pharmaceuticals and medical devices, though industry players ...

Markets tumble as Nifty falls below 25,000 due to FII selling and mixed earnings, impacting investor sentiment.